Enterprise Value
1.42B
Cash
940.8M
Avg Qtr Burn
-5.188M
Short % of Float
7.94%
Insider Ownership
1.22%
Institutional Own.
85.56%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Gemcitabine & Nab-paclitaxel w/ NovoTTF-200T Details Pancreatic cancer | Phase 3 Data readout | |
Stereotactic radiosurgery (SRS) w/ NovoTTF-200M Details Non-small cell lung carcinoma, Brain metastases Big Mover™ Suspected Mover™ Susp. Mover™ | Phase 3 Data readout | |
Immune checkpoint inhibitors or docetaxel w/ NovoTTF-200T Details Non-small cell lung carcinoma | Phase 3 Update | |
Paclitaxel w/ NovoTTF-100L(O) Details Ovarian cancer | Phase 3 Update |